Ricardo P. Casaroli-Marano, Belén Alvarez-Palomo, Michael J. Edel, Joaquim Vives, Luciano Rodriguez Gómez, Susana Gómez, Sergi Querol Giner, Institut Català de la Salut, [Alvarez-Palomo B, Gomez SG, Rodriguez Gómez L] Banc de Sang i Teixits, Barcelona, Spain. [Vives J] Banc de Sang i Teixits, Barcelona, Spain. Grup de Enginyeria tissular musculoesquelètica, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. [Casaroli-Marano RP] Banc de Sang i Teixits, Barcelona, Spain. Departament de Cirurgia, Facultat de Medicina, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain. Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona, Spain. [Edel MJ] Laboratori de Genètica molecular i control de Pluripotència, Departament de Biomedicina, Institut de Neurociències, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain. Victor Chang Cardiac Research Institute, Sydney, Australia. Harry Perkins Research Institute, Centre for Cell Therapy and Regenerative Medicine (CCTRM), School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. Department of Physiology, Anatomy and Genetics, Oxford University, Oxford, UK. Centro de Oftalmología Barraquer, Institut Universitari Barraquer, Universitat Autònoma de Barcelona, Barcelona, Spain. [Querol Giner S] Banc de Sang i Teixits, Barcelona, Spain. Grup de Enginyeria tissular musculoesquelètica, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain., and Vall d'Hebron Barcelona Hospital Campus
HLA haplobank; SOP; Cell therapy Haplobanc d'HLA; Procediment operatiu estàndard; Teràpia cel·lular Haplobanco de HLA; Procedimiento operativo estándar; Terapia celular In this article, we will discuss the main aspects to be considered to define standard operation procedures (SOPs) for the creation of an induced pluripotent stem cell (iPSC) bank using cord blood (CB)-or similar cell type-bank guidelines for clinical aims. To do this, we adapt the pre-existing SOP for CB banking that can be complementary for iPSCs. Some aspects of iPSC manufacturing and the particular nature of these cells call for special attention, such as the potential multiple applications of the cells, proper explanation to the donor for consent of use, the genomic stability and the risk of genetic privacy disclosure. Some aspects of the iPSC SOP are solidly established by CB banking procedures, other procedures have good consensus in the scientific and medical community, while others still need to be further debated and settled. Given the international sharing vocation of iPSC banking, there is an urgent need by scientists, clinicians and regulators internationally to harmonize standards and allow future sample interchange between many iPSC bank initiatives that are springing up worldwide. Funded by Spanish Ministry of Science, Innovation and Universities, National Plan for Scientific and Technical Research and Innovation 2013–2016 RETOS COLABORACIÓN Program 2017: exp. RTC-2017-6000-1. 2017–2021; Spanish Cell Therapy Network (TerCel, exp. No. RD16/0011/0028); AdvanceCat with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) under the Catalonian ERDF operational program (European Regional Development Fund) 2014–2020; TV3 Maraton 2018–FBG project 309768 (M.J.E)